NuvaRing (etonogestrel, ethinyl estradiol)
Jump to navigation
Jump to search
Introduction
A vaginal contraceptive ring. FDA approved 2001
Dosage
- leave ring in for 3 weeks; remove for 4th week of cycle
- if ring is expelled, may be washed & resinserted
- use back-up contraception if ring has been removed > 3 hours
- continue backup contraception until ring has been in place 7 days
Adverse effects
- 2-fold increased risk relative to oral contraceptives[4]
Mechanism of action
- small vaginal ring
- releases etonogestrel + ethinyl estradiol
Notes
- lowest estrogen exposure vs patch, oral contraceptive[3]
More general terms
Components
References
- ↑ Prescriber's Letter 9(2):S1 2002
- ↑ Prescriber's Letter 9(6):32 2002
- ↑ 3.0 3.1 van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005 Sep;72(3):168-74. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16102549
- ↑ 4.0 4.1 Lidegaard O et al Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 BMJ 2012;344:e2990 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22577198 <Internet> http://www.bmj.com/content/344/bmj.e2990
- ↑ Lidegaard O et al Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception N Engl J Med 2012; 366:2257-2266June 14, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22693997 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1111840
Petitti DB Hormonal Contraceptives and Arterial Thrombosis - Not Risk-free but Safe Enough N Engl J Med 2012; 366:2316-2318June 14, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22694003 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1204769 - ↑ Organon. http://www.nuvaring.com